[{"from": "human", "value": "Provide a brief overview of this molecule. [C][N][C][=C][Branch2][Ring2][Branch1][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][C][=N][C][=C][Branch1][Ring2][N][Ring1][Branch1][C][Branch1][C][F][Branch1][C][F][F][N][=C][Ring2][Ring1][=Branch2][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][Branch1][C][F][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable small molecule with potential antineoplastic activity. CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibits vascular endothelial growth factor receptor type 2 (VEGFR-2), thereby disrupting tumor angiogenesis. Raf kinases are critical enzymes in the Ras/Raf/MEK/ERK signaling pathway and are frequently upregulated in neoplasms."}]